A Randomized Clinical Trial of Oral Magnesium Supplementation in Pregnancy
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The investigators propose a preventive strategy that may reduce the risk of placental
vascular disease and its negative consequences for both the fetus (e.g., poor fetal growth or
stillbirth)and mother (e.g., the hypertensive disorders of pregnancy), and which, in turn,
should reduce the need for indicated preterm delivery. This strategy is a multicenter,
randomized double-blind, placebo-controlled clinical trial (RCT) comparing magnesium citrate
supplementation with placebo, each starting at 12 to 20 weeks gestation and continued until
delivery. Magnesium citrate is a safe and inexpensive compound that is easily absorbed by the
intestinal tract. The results of this RCT may be especially relevant in low and middle income
countries that have high rates of prematurity, and limited resources for acute newborn and
maternal care.
Phase:
Phase 3
Details
Lead Sponsor:
Professor Fernando Figueira Integral Medicine Institute